Enantioselective total synthesis of (+)-vincamine

Citation: Fanglin Xue, Hengmao Liu, Rui Wang, Dan Zhang, Hao Song, Xiao-Yu Liu, Yong Qin. Enantioselective total synthesis of (+)-vincamine[J]. Chinese Chemical Letters, 2022, 33(4): 2044-2046. doi: 10.1016/j.cclet.2021.09.032 shu

Enantioselective total synthesis of (+)-vincamine

English

Enantioselective total synthesis of (+)-vincamine

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
^* Corresponding authors.
E-mail addresses: songhao@scu.edu.cn (H. Song)
yongqin@scu.edu.cn (Y. Qin).
Received Date: 23 July 2021
Accepted Date: 07 September 2021
Revised Date: 02 September 2021
Available Online: 15 April 2022

Abstract: A catalytic asymmetric total synthesis of (+)-vincamine is presented. Key features of the synthesis include a Pd-catalyzed enantioselective decarboxylative allylation to form the C20 quaternary stereogenic center and a stereoselective iminium reduction to install the critical cis-C20/C21 relative stereochemisty.

Key words:

The eburnamine-vincamine monoterpenoid indole alkaloids represent a large group of natural products found from the plants of genus Hunteria, Vinca, and Kopsia [1-8]. (+)-Vincamine (1, Fig. 1) is a unique member in this alkaloid subfamily that displays significant pharmacological activities and has been used as a peripheral vasodilator and nootropic agent in clinic [9-13]. Additionally, other selected compounds belonging to this subfamily of alkaloids include (−)-eburnamonine (2), (−)-19-OH-eburnamonine (3), and unnatural (−)-20-epi-vincamine (4). Due to their significant pharmacological activities and limited natural abundance [14], the eburnamine-vincamine indole alkaloids became privileged synthetic targets for decades, which has resulted in a number of successful total syntheses [15-59].

Figure 1

Figure 1. The structures of (+)-vincamine and related monoterpenoid indole alkaloids.

DownLoad: Full-Size Img PowerPoint

Despite the numerous efforts, two critical issues remain to be addressed toward an efficient enantioselective synthesis of the eburnamine-vincamine alkaloids. On one hand, catalytic asymmetric protocols for establishing the stereogenic chiral centers in these complex target molecules have been limited [36, 42, 46]. The most known synthetic approaches to enantioenriched eburnamine-vincamine alkaloids relied on resolution, chiral pool or chiral auxiliary methods [23-35, 37−41, 43-45, 52, 56, 57, 59]. On the other hand, control of the cis-C20/C21 relative stereochemistry represents a key challenge in accessing the eburnamine-vincamine alkaloids [58]. Recent endeavours in this research field have been particularly focused on solving the above-mentioned two issues. For example, Zhu and co-workers reported a conformation-directed cyclization process to selectively control the cis-C20/C21 stereochemistry in their total synthesis of (±)-eburnamonine [58]. In 2019, the Trost group documented an enantioselective synthesis of C19-oxo eburnane alkaloids (e.g., 3) featuring a new Pd-catalyzed asymmetric allylation reaction [57]. Recently, Chen, Tang, and colleagues developed an Ir-catalyzed asymmetric imine hydrogenation/lactamization cascade strategy to install the trans-C20/C21 stereocenters (dr = 7.4:1) in their synthesis of (−)-4 [59]. During our preparation of this manuscript, Stoltz et al. published a catalytic asymmetric synthesis of (+)-eburnamonine ((+)-2) with 3.4:1 dr in the formation of the C20/C21 relative stereochemistry [46]. Our group previously described a photocatalytic radical cascade approach to (−)-vincamine ((−)-1) [36]. However, the key step (i.e., 6 to 7, Scheme 1) suffered from low diastereoselectivity (cis: trans = 3:2) of the C20/C21 relative stereochemistry. As part of our long-lasting interest in the total synthesis of complex alkaloid natural products [60-62], here we disclose our second-generation synthesis of (+)-vincamine (1) with excellent control of both the enantioselectivity and diastereoselectivity.

Scheme 1

Scheme 1. Our two generations of asymmetric synthetic approaches to vincamine.

DownLoad: Full-Size Img PowerPoint

Our retrosynthetic analysis of (+)-vincamine (1) is outlined in Scheme 2. According to known strategies, the E ring in 1 could be formed at the late stage of the synthesis through lactamization and subsequent rearrangement of 10. Preparation of the tetracyclic compound 10 could rely on a Bischler-Napieralski cyclization/iminium reduction sequence of amide 9, which would not only construct the C ring but also establish the configuration of the newly generated stereocenter at C21. We envisioned that introduction of a sterically hindered tetramethyl dioxolane group at the C20 side chain would greatly block the upper face of the iminium functionality in intermediate 11, thus securing a C20/C21 cis-relationship after iminium reduction. In turn, amide 9 could be prepared via N-alkylation of 12 using the indole fragment 13 as the electrophile. Finally, the quaternary stereocenter in 12 could be generated by an asymmetric decarboxylative allylation of 14 based on the Stoltz protocol [63].

Scheme 2

Scheme 2. Retrosynthetic analysis of (+)-vincamine (1).

DownLoad: Full-Size Img PowerPoint

The first challenge in the asymmetric synthesis of vincamine was to efficiently construct the all-carbon quaternary stereocenter at C20. Over the past decade, the Pd-catalyzed enantioselective allylic alkylation reaction has been a powerful tool for the construction of all-carbon quaternary stereocenters [64-67]. Our total synthesis commenced with the Pd-catalyzed enantioselective decarboxylative allylation of racemic lactam 14 (Scheme 3). Based on the slightly modified conditions (Pd₂(pmdba)₃ (5 mol%), 15 (12.5 mol%), PhMe (0.1 mol/L), 70 ℃) of Stoltz's report, we were able to obtain N-Bz piperidinone 8 with 93% yield and 98% ee on a gram scale [63]. Ozonolysis of the terminal alkene in 8 in CH₂Cl₂ at −78 ℃ afforded aldehyde 16 with excellent efficiency (97% yield). Olefination of aldehyde 16 by Wittig reaction using methoxymethylene phosphonium chloride, followed by hydrolysis of the resulting methyl enol ether provided 17 in 87% yield over two steps. Subsequently, condensation of aldehyde 17 and pinacol in the presence of p-toluenesulfonic acid delivered acetal 18 (95% yield). Removal of the N-Bz group of 18 under basic conditions (LiOH·H₂O, MeOH) gave the chiral lactam 12.

Scheme 3

Scheme 3. Synthesis of the chiral building block 12.

DownLoad: Full-Size Img PowerPoint

With the chiral building block 12 secured, we turned our attention to the linkage of 12 with an indole motif (Scheme 4). Direct N-alkylation of lactam 12 with β-indolyl electrophiles proved challenging due to the instability of the latter under basic conditions. This problem was also encountered by Stoltz et al. in their recent synthesis of (+)-eburnamonine [46], who ultimately employed a stepwise approach to introduce the indole moiety. In our hand, after extensive experimentation, we were delighted to observe that tosylate 13 was a capable substrate to react with lactam 12 using NaH in THF at 60 ℃ to give the desired product 19 in 89% yield [68]. Removal of the tosyl group at the indole N-atom in 19 through treatment with Mg/MeOH yielded 9. At this stage, the key Bischler-Napieralski cyclization/iminium reduction sequence of amide 9 was explored. Subjecting 9 to 2-F-pyridine and Tf₂O in CH₂Cl₂ smoothly generated the iminium intermediate 11 (Scheme 2) [69-72]. After screening various reduction conditions (NaBHEt₃, NaBH(OAc)₃, NaBH₃CN, DIBAL-H, l-selectride, LDBBA, H₂/Pd-C, etc.), we found that the use of LiAlH(Ot-Bu)₃ at −78 ℃ furnished the tetracyclic product 10 with the optimal diastereoselectivity (dr = 11:1) in 82% yield over two steps. The above transformation (9 to 10) was easily conducted on a 4 g scale, which delivered the key intermediate 10 with requisite cis-C20/C21 stereochemistry in gram quantity with enhanced enantiomerical purity (99.7% ee) after recrystallization with acetone/water (4:1). Next, removal of the acetal group in 10 followed by oxidation of the resulting hemiaminal (structure not shown) according to Iwabuchi's method [73] produced lactam 20, a known precursor to (+)-vincamine [32]. Davis oxidation of 20 installed the C17-OH group and delivered hydroxyl lactam 22 [59]. Finally, MnO₂-mediated oxidation of 22 and subsequent NaOMe-promoted rearrangement afforded (+)-vincamine (1) in 65% yield over two steps [26].

Scheme 4

Scheme 4. Total synthesis of (+)-vincamine (1).

DownLoad: Full-Size Img PowerPoint

In conclusion, we have established a practical and concise approach to catalytic asymmetric total synthesis of the biologically important indole alkaloid (+)-vincamine in 14 steps and 16.2% overall yield. To a large extent, the current synthesis addressed the two major selectivity issues that have long puzzled the synthetic community by taking advantage of a Pd-catalyzed enantioselective decarboxylative allylation and a diastereoselective iminium reduction as key steps. Consequently, this synthetic strategy provides a general way to prepare other members and derivatives of the eburnamine-vincamine alkaloids possessing cis-C20/C21 stereocenters.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

We gratefully acknowledge the National Natural Science Foundation of China (Nos. 21991114, 21921002 and 21732005) for financial support.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2021.09.032.
1. [1]
  J.E. Saxton, The eburnamine–vincamine group, in: A. Weissberger, E. Taylor (Eds.), Indoles Part IV: The Monoterpene Indole Alkaloids, Wiley, New York, 1983, pp. 439–465.
2. [2]
  Atta-ur-Rahman, M. SultanaS., Heterocycles 22 (1984) 841–858. doi: 10.3987/R-1984-04-0841
3. [3]
  M. Lounasmaa, A. Tolvanen, Eburnamine–vincamine alkaloids, in: G.A. Cordell (Ed. ), The Alkaloids: Chemistry and Pharmacology, Academic Press, New York, 1992, pp. 1–116.
4. [4]
  J.E. Saxton, Nat. Prod. Rep. 11 (1994) 493–531.
5. [5]
  J.E. Saxton, Nat. Prod. Rep. 13 (1996) 327–363.
6. [6]
  J.E. Saxton, Nat. Prod. Rep. 14 (1997) 559–590. doi: 10.1039/np9971400559
7. [7]
  J. Leonard, Nat. Prod. Rep. 16 (1999) 319–338.
8. [8]
  M.H. Zenk, M. Juenger, Phytochemistry 68 (2007) 2757–2772.
9. [9]
  P. Cook, I. James, N. Engl. J. Med. 305 (1981) 1560–1564.
10. [10]
  H.R. Olpe, G. Barrionuevo, G. Lynch, Life Sci. 31 (1982) 1947–1953.
11. [11]
  Á. Vas, B. Gulyás, Med. Res. Rev. 25 (2005) 737–757. doi: 10.1002/med.20043
12. [12]
  A. Nemes, Monoterpenoid indole alkaloids, CNS and anticancer drugs, in J. Fischer, C.R. Ganellin (Eds. ), Analogue-Based Drug Discovery II, Wiley, Weinheim, 2010, pp. 189–215.
13. [13]
  A.H.A. Fayed, Biol. Trace Elem. Res. 136 (2010) 314–319. doi: 10.1007/s12011-009-8550-3
14. [14]
  Y. Wang, Extraction, Separation, Purification, And Qualitative And Quantitative Analysis Of Vincamine in Vinca minor L, M.S. Thesis, Northwest University, 2009.
15. [15]
  M.E. Kuehne, J. Am. Chem. Soc. 86 (1964) 2946. doi: 10.1021/ja01068a044
16. [16]
  K.H. Gibson, J.E. Saxton, J. Chem. Soc. D 799 (1969) 1490.
17. [17]
  J.L. Herrmann, R.J. Cregge, J.E. Richman, C.L. Semmelhack, R.H. Schlessinger, J. Am. Chem. Soc. 96 (1974) 3702–3703. doi: 10.1021/ja00818a083
18. [18]
  K.H. Gibson, J.E. Saxton, Tetrahedron 33 (1977) 833–836.
19. [19]
  J.L. Herrmann, R.J. Cregge, J.E. Richman, et al., J. Am. Chem. Soc. 101 (1979) 1540–1544. doi: 10.1021/ja00500a028
20. [20]
  D. Genin, R.Z. Andriamialisoa, N. Langlois, Y. Langlois, J. Org. Chem. 52 (1987) 353–356. doi: 10.1021/jo00379a007
21. [21]
  Z. Koblicová, J. Holubek, J. Trojánek, Collect. Czech. Chem. Commun. 53 (1988) 2722–2730. doi: 10.1135/cccc19882722
22. [22]
  M. Lounasmaa, A. Tolvanen, J. Org. Chem. 55 (1990) 4044–4047. doi: 10.1021/jo00300a019
23. [23]
  C. Szántay, L. Szabó, G. Kalaus, Tetrahedron Lett. 14 (1973) 191–192.
24. [24]
  P. Pfäfi, W. Oppolzer, R. Wenger, H. Hauth, Helv. Chim. Acta. 58 (1975) 1131–1145.
25. [25]
  W. Oppolzer, H. Hauth, P. Pfäfi, R. Wenger, Helv. Chim. Acta. 60 (1977) 1801–1810. doi: 10.1002/hlca.19770600533
26. [26]
  C. Szántay, L. Szabó, G. Kalaus, Tetrahedron 33 (1977) 1803–1808.
27. [27]
  G. Rossey, A. Wick, E. Wenkert, J. Org. Chem. 47 (1982) 4745–4749. doi: 10.1021/jo00145a028
28. [28]
  L. Szabó, G. Kalaus, C. Szántay, Arch. Pharm. 316 (1983) 629–638. doi: 10.1002/ardp.19833160709
29. [29]
  L. Szabó, J. Sápi, G. Kalaus, et al., Tetrahedron 39 (1983) 3737–3747.
30. [30]
  K. Hakam, M. Thielmann, T. Thielmann, E. Winterfeldt, Tetrahedron 43 (1987) 2035–2044.
31. [31]
  P. Gmeiner, P.L. Feldman, M.Y. Chu-Moyer, H. Rapoport, J. Org. Chem. 55 (1990) 3068–3074. doi: 10.1021/jo00297a023
32. [32]
  D. Desmaële, K. Mekouar, J. d'Angelo, J. Org. Chem. 62 (1997) 3890–3901.
33. [33]
  T. Nagy, L. Szabó, G. Kalaus, C. Szántay, Heterocycles 45 (1997) 2007–2013.
34. [34]
  A.G. Schultz, W.P. Malachowski, Y. Pan, J. Org. Chem. 62 (1997) 1223–1229.
35. [35]
  J.C.F. Alves, A.B.C. Simas, P.R.R. Costa, Tetrahedron 10 (1999) 297–306.
36. [36]
  X. Wang, D. Xia, W. Qin, et al., Chem 2 (2017) 803–816.
37. [37]
  L. Novák, J. Rohály, C. Szántay, L. Czibula, Heterocycles 6 (1977) 1149–1156.
38. [38]
  P. Magnus, P. Brown, J. Chem. Soc. Chem. Commun. 4 (1985) 184–186.
39. [39]
  M. Node, H. Nagasawa, K. Fuji, J. Am. Chem. Soc. 109 (1987) 7901–7903. doi: 10.1021/ja00259a060
40. [40]
  M. Node, H. Nagasawa, K. Fuji, J. Org. Chem. 55 (1990) 517–521. doi: 10.1021/jo00289a025
41. [41]
  A.G. Schultz, L. Pettus, J. Org. Chem. 62 (1997) 6855–6861.
42. [42]
  D.S. Liyanage, C.S. Jungong, A.V. Novikov, Tetrahedron Lett. 56 (2015) 2269–2271.
43. [43]
  K.R. Prasad, J.E. Nidhiry, Synlett 23 (2012) 1477–1480. doi: 10.1055/s-0031-1291143
44. [44]
  J.E. Nidhiry, K.R. Prasad, Tetrahedron 69 (2013) 5525–5536.
45. [45]
  G. Pandey, A. Mishra, J. Khamrai, Org. Lett. 19 (2017) 3267–3270. doi: 10.1021/acs.orglett.7b01410
46. [46]
  C. Reimann, A. Ngamnithiporn, K. Hayashida, et al., Angew. Chem. Int. Ed. 60 (2021) 17957–17962. doi: 10.1002/anie.202106184
47. [47]
  M. Lounasmaa, E. Karvinen, Heterocycles 36 (1993) 751–760. doi: 10.3987/COM-92-6220
48. [48]
  D.B. England, A. Padwa, Org. Lett. 9 (2007) 3249–3252. doi: 10.1021/ol071173x
49. [49]
  D.B. England, A. Padwa, J. Org. Chem. 73 (2008) 2792–2802. doi: 10.1021/jo8001003
50. [50]
  M.W. Smith, R. Hunter, D.J. Patten, W. Hinz, Tetrahedron. Lett. 50 (2009) 6342–6346.
51. [51]
  D.R. Bobeck, H.I. Lee, A.C. Flick, A. Padwa, J. Org. Chem. 74 (2009) 7389–7402. doi: 10.1021/jo901336z
52. [52]
  C. Piemontesi, Q. Wang, J. Zhu, Angew. Chem. Int. Ed. 55 (2016) 6556–6560. doi: 10.1002/anie.201602374
53. [53]
  P. Mondal, N.P. Argade, Org. Biomol. Chem. 14 (2016) 10394-10406. doi: 10.1039/C6OB01438K
54. [54]
  L. Salacz, C. Charpentier, J. Suffert, N. Girard, J. Org. Chem. 82 (2017) 2257–2262. doi: 10.1021/acs.joc.6b02939
55. [55]
  P. Mondal, N.P. Argade, Synthesis 49 (2017) 1849–1856.
56. [56]
  Q. Zhou, X. Dai, H. Song, et al., Chem. Commun. 54 (2018), 9510–9512. doi: 10.1039/c8cc05374j
57. [57]
  B.M. Trost, Y. Bai, W.J. Bai, J.E. Schultz, J. Am. Chem. Soc. 141 (2019) 4811–4814. doi: 10.1021/jacs.9b00788
58. [58]
  G. Li, C. Piemontesi, Q. Wang, J. Zhu, Angew. Chem. Int. Ed. 58 (2019) 2870–2874. doi: 10.1002/anie.201813920
59. [59]
  W. Zhang, X. Chen, Y. An, et al., Chem. Eur. J. 26 (2020) 10439–10443. doi: 10.1002/chem.202002404
60. [60]
  D. Zhang, H. Song, Y. Qin, Acc. Chem. Res. 44 (2011) 447–457.
61. [61]
  X.Y. Liu, Y. Qin, Acc. Chem. Res. 52 (2019) 1877–1891. doi: 10.1021/acs.accounts.9b00246
62. [62]
  X.Y. Liu, F.P. Wang, Y. Qin, Acc. Chem. Res. 54 (2021) 22–34. doi: 10.1021/acs.accounts.0c00720
63. [63]
  D. C. Behenna, Y. Liu, T. Yurino, et al., Nat. Chem. 4 (2012) 130–133. doi: 10.1038/nchem.1222
64. [64]
  B.M. Trost, Tetrahedron 71 (2015) 5708–5733.
65. [65]
  A.Y. Hong, B.M. Stoltz, Eur. J. Org. Chem. 14 (2013) 2745–2759. doi: 10.1002/ejoc.201201761
66. [66]
  B.P. Pritchett, B.M. Stoltz, Nat. Prod. Rep. 35 (2018) 559–574.
67. [67]
  O. Pamies, J. Margalef, S. Canellas, et al., Chem. Rev. 121 (2021) 4373-4505. doi: 10.1021/acs.chemrev.0c00736
68. [68]
  C. Xie, J. Luo, Y. Zhang, et al., Org. Lett. 20 (2018) 2386–2390. doi: 10.1021/acs.orglett.8b00725
69. [69]
  G. Barbe, A.B. Charette, J. Am. Chem. Soc. 130 (2008) 18–19. doi: 10.1021/ja077463q
70. [70]
  G. Pelletier, W.S. Bechara, A.B. Charette, J. Am. Chem. Soc. 132 (2010) 12817–12819. doi: 10.1021/ja105194s
71. [71]
  K.L. White, M. Mewald, M. Movassaghi, J. Org. Chem. 80 (2015) 7403–7411. doi: 10.1021/acs.joc.5b01023
72. [72]
  T. Kang, K.L. White, T.J. Mann, A.H. Hoveyda, M. Movassaghi, Angew. Chem. Int. Ed. 56 (2017) 13857–3860. doi: 10.1002/anie.201708088
73. [73]
  Y. Sasano, S. Nagasawa, M. Yamazaki, et al., Angew. Chem. Int. Ed. 53 (2014) 3236–3240. doi: 10.1002/anie.201309634
Figure 1 The structures of (+)-vincamine and related monoterpenoid indole alkaloids.

下载: 全尺寸图片幻灯片

Scheme 1 Our two generations of asymmetric synthetic approaches to vincamine.

下载: 全尺寸图片幻灯片

Scheme 2 Retrosynthetic analysis of (+)-vincamine (1).

下载: 全尺寸图片幻灯片

Scheme 3 Synthesis of the chiral building block 12.

下载: 全尺寸图片幻灯片

Scheme 4 Total synthesis of (+)-vincamine (1).

下载: 全尺寸图片幻灯片